▶주메뉴 바로가기
▶본문 바로가기
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on A...
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1...
The Korea Exchange, South Korea’s stock market operator, on Aug. 26 announced its decision to delist troubled Kolon Group ’s US gene therapy-developing unit Kolon TissueGene . In late March, a c...
Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the ...
South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its ...
Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on...
SillaJen shares bottomed out on Aug. 2 on news that the global phase 3 clinical trials of its signature liver cancer treatment Pexa-Vec are likely to be suspended. The biotech firm trading on South...
Celltrion announced on Aug. 1 that it had started a phase 3 clinical trial of its new drug Remsima SC in the US. Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of J...
South Korean pharmaceutical firm Samsung Bioepis said on July 24 it has won approval from the US Food and Drug Administration to sell one of its biosimilars in the United States. Hadlima, referen...
The value of stocks owned by both former and current entertainment agency owners in South Korea dropped nearly 30 percent compared to last year, data showed on July 21, as the industry is struggling ...
Three-dimensional printing of human organs is not some far-fetched fiction. Active research of the relevant technologies has gained pace around the globe, especially here in South Korea, where the ac...
South Korean biopharma firms Chong Kun Dang and Dong-A ST expect to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Ja...
Celltrion announced July 19 that it has established the joint venture Vcell Healthcare in Shanghai with Hong Kong-based conglomerate Nan Fung Group to make a foray into China. Established in 1954, N...
HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, invested 5.6 billion won ($4.76 million) in Switzerland-based biotech startup Roivant Sciences’ subsidiary Immunovant Sciences, according ...
Korean biotech firm Bridge Biotherapeutics announced on July 18 that it has signed a contract with German-based pharmaceutical company Boehringer Ingelheim to license out its drug candidate BBT-877. ...
[Market Close-up] S. Korean stock market recovers faster than other markets
One Equity Partners to unload Celltrion Healthcare stake at discount
Local telecom firms bid for fifth-largest cable TV operator Hyundai HCN
IBK fined $86m in US over mishandling anti-money laundering program
Acleda Bank lists on KRX-invested Cambodian stock exchange
Samsung Biologics bags CMO deals worth W468b
Tmon vows to turn profit by 10th anniversary
Macrogen’s COVID-19 test kit approved for export
May 27, 2020
![[Market Close-up] S. Korean stock market recovers faster than other markets](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2020/05/27/20200527000702_0.jpg&md=20200527162557)
